Merck's Recent Gains May Be a Red Flag for Investors

Merck's stock price has risen significantly over the past six months, beating the S&P 500 by 13.4% and climbing to $149.98.

This growth may have investors wondering if there is a buying opportunity in Merck or if it presents a risk to their portfolio.

Despite its recent success, our expert analysts are cautious about Merck's prospects due to three main reasons.

The first reason is the company's weak constant currency revenue growth, which averaged 3.8% year-on-year over the last two years and lags behind the sector.

This suggests that Merck may need to lower prices or invest in product improvements to accelerate growth, which could hinder near-term profitability.

The second reason is the company's shrinking adjusted operating margin, which decreased by 19.9 percentage points over the last five years.

This raises questions about Merck's expense base and whether its revenue growth has given it leverage on its fixed costs, resulting in better economies of scale and profitability.

The third reason is the decline in earnings per share (EPS), which fell by 11.1% annually over the last five years while revenue grew by 7.9%.

This indicates that Merck has become less profitable on a per-share basis as it expanded, making its current valuation of 17 times forward P/E seem reasonable but not exciting.